192 related articles for article (PubMed ID: 29383821)
1. Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice.
Morser J; Shao Z; Nishimura T; Zhou Q; Zhao L; Higgins J; Leung LLK
J Thromb Haemost; 2018 May; 16(5):991-1002. PubMed ID: 29383821
[TBL] [Abstract][Full Text] [Related]
2. Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity.
Leung LLK; Morser J
J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29883024
[TBL] [Abstract][Full Text] [Related]
3. Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.
Shao Z; Nishimura T; Leung LL; Morser J
J Thromb Haemost; 2015 Jun; 13(6):1090-102. PubMed ID: 25851247
[TBL] [Abstract][Full Text] [Related]
4. Targeted disruption of the gene encoding the murine small subunit of carboxypeptidase N (CPN1) causes susceptibility to C5a anaphylatoxin-mediated shock.
Mueller-Ortiz SL; Wang D; Morales JE; Li L; Chang JY; Wetsel RA
J Immunol; 2009 May; 182(10):6533-9. PubMed ID: 19414808
[TBL] [Abstract][Full Text] [Related]
5. Both plasma basic carboxypeptidases, carboxypeptidase B2 and carboxypeptidase N, regulate vascular leakage activity in mice.
Zhou Q; Zhao L; Shao Z; Declerck P; Leung LLK; Morser J
J Thromb Haemost; 2022 Jan; 20(1):238-244. PubMed ID: 34626062
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N.
Campbell WD; Lazoura E; Okada N; Okada H
Microbiol Immunol; 2002; 46(2):131-4. PubMed ID: 11939578
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory and anti-fibrinolytic effects of thrombomodulin alfa through carboxypeptidase B2 in the presence of thrombin.
Tawara S; Sakai T; Matsuzaki O
Thromb Res; 2016 Nov; 147():72-79. PubMed ID: 27693845
[TBL] [Abstract][Full Text] [Related]
8. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice.
Asai S; Sato T; Tada T; Miyamoto T; Kimbara N; Motoyama N; Okada H; Okada N
J Immunol; 2004 Oct; 173(7):4669-74. PubMed ID: 15383602
[TBL] [Abstract][Full Text] [Related]
9. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
[TBL] [Abstract][Full Text] [Related]
10. Complement component c5a is integral to the febrile response of mice to lipopolysaccharide.
Li S; Boackle SA; Holers VM; Lambris JD; Blatteis CM
Neuroimmunomodulation; 2005; 12(2):67-80. PubMed ID: 15785108
[TBL] [Abstract][Full Text] [Related]
11. Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.
Hu X; Wetsel RA; Ramos TN; Mueller-Ortiz SL; Schoeb TR; Barnum SR
Immunobiology; 2014 Feb; 219(2):104-8. PubMed ID: 24028840
[TBL] [Abstract][Full Text] [Related]
12. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis.
Campbell W; Okada N; Okada H
Immunol Rev; 2001 Apr; 180():162-7. PubMed ID: 11414358
[TBL] [Abstract][Full Text] [Related]
13. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not.
Sato T; Miwa T; Akatsu H; Matsukawa N; Obata K; Okada N; Campbell W; Okada H
J Immunol; 2000 Jul; 165(2):1053-8. PubMed ID: 10878383
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil chemotactic activity and C5a following systemic activation of complement in rats.
Schmid E; Warner RL; Crouch LD; Friedl HP; Till GO; Hugli TE; Ward PA
Inflammation; 1997 Jun; 21(3):325-33. PubMed ID: 9246574
[TBL] [Abstract][Full Text] [Related]
15. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.
Ozaki M; Kang Y; Tan YS; Pavlov VI; Liu B; Boyle DC; Kushak RI; Skjoedt MO; Grabowski EF; Taira Y; Stahl GL
Kidney Int; 2016 Oct; 90(4):774-82. PubMed ID: 27378476
[TBL] [Abstract][Full Text] [Related]
16. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.
Ståhl AL; Sartz L; Karpman D
Blood; 2011 May; 117(20):5503-13. PubMed ID: 21447825
[TBL] [Abstract][Full Text] [Related]
17. Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats.
Proctor LM; Strachan AJ; Woodruff TM; Mahadevan IB; Williams HM; Shiels IA; Taylor SM
Int Immunopharmacol; 2006 Aug; 6(8):1224-32. PubMed ID: 16782534
[TBL] [Abstract][Full Text] [Related]
18. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
[TBL] [Abstract][Full Text] [Related]
19. Deletion of carboxypeptidase N delays onset of experimental cerebral malaria.
Darley MM; Ramos TN; Wetsel RA; Barnum SR
Parasite Immunol; 2012; 34(8-9):444-7. PubMed ID: 22708514
[TBL] [Abstract][Full Text] [Related]
20. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).
Caillaud C; Zaloszyc A; Licht C; Pichault V; Frémeaux-Bacchi V; Fischbach M
Pediatr Nephrol; 2016 Jan; 31(1):157-61. PubMed ID: 26399238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
